The biopharmaceuticals CDMO market continues to grow in double digits annually and the expansion allows AGC Biologics to strengthen its market position. This investment will more than double AGC Biologics’ single-use bioreactor mammalian cell-culture capacity in Copenhagen. AGC’s other biologics facilities are in Seattle WA, Boulder CO and Chiba, Japan.
“We are excited to announce the groundbreaking of the new facility,” said Patricio Massera, CEO, AGC Biologics. “We are fully committed to understand and meet our customers’ needs, as we continuously seek to provide new capacity and new services.”
Andrea C. Porchia, Copenhagen site head, AGC Biologics, said, “We are now establishing a new state-of-the-art facility with a flexible and efficient set-up for biologic drug substance manufacturing. It will be a great facility and we are looking forward to making it available for existing and new customers.”